RE:Ladies time to change your panties. BetterLife Pharma (CSE: BETR). BETR is NIA's #1 overall pick for 2021. Yesterday, BETR began to breakout big and gained by $0.36 or 21.95% to close at $2 per share, its highestclosing price since becoming a psychedelic company! BETR will quickly be launching their IIS in 1Q 2021 for their Second Generation LSD product TD-0148A in preparation of their IND to launch Phase 1-2 FDA clinical trials in 3Q-4Q 2021. BETR's two patents that allow for the manufacturing of TD-0148A without the need to actually make LSD puts BETR in a better position than MindMed (MMEDF). We believe BETR to be the best way to capitalize on the therapeutic potential of LSD because TD-0148A mimics the therapeutic effects of LSD without the hallucinations.BETR's patents eliminate significant regulatory controls that will be required for MMEDF if it ever begins conducting FDA trials of its own. BETR's CEOpreviously founded Merus Labs, which he took to the NASDAQ before the company was acquired in 2017 for US$270 million.